Short Interest in Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Increases By 13.6%

Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) was the recipient of a significant increase in short interest in January. As of January 15th, there was short interest totalling 595,300 shares, an increase of 13.6% from the December 31st total of 523,900 shares. Based on an average daily volume of 260,300 shares, the short-interest ratio is presently 2.3 days. Approximately 7.5% of the shares of the stock are short sold.

Institutional Trading of Citius Pharmaceuticals

Several hedge funds have recently made changes to their positions in the business. Chelsea Counsel Co. increased its stake in Citius Pharmaceuticals by 9.8% during the third quarter. Chelsea Counsel Co. now owns 281,300 shares of the company’s stock worth $141,000 after acquiring an additional 25,000 shares during the last quarter. Virtu Financial LLC purchased a new position in shares of Citius Pharmaceuticals in the 3rd quarter worth approximately $50,000. Geode Capital Management LLC increased its position in shares of Citius Pharmaceuticals by 14.1% during the 3rd quarter. Geode Capital Management LLC now owns 1,878,953 shares of the company’s stock valued at $941,000 after purchasing an additional 232,656 shares during the last quarter. XTX Topco Ltd purchased a new stake in Citius Pharmaceuticals during the 3rd quarter valued at $47,000. Finally, Miller Investment Management LP raised its holdings in Citius Pharmaceuticals by 99.3% during the 3rd quarter. Miller Investment Management LP now owns 99,640 shares of the company’s stock valued at $50,000 after buying an additional 49,640 shares during the period. 16.88% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

CTXR has been the topic of a number of research analyst reports. D. Boral Capital reiterated a “buy” rating and issued a $9.00 target price on shares of Citius Pharmaceuticals in a research report on Tuesday, January 7th. HC Wainwright reaffirmed a “buy” rating and set a $100.00 price objective on shares of Citius Pharmaceuticals in a report on Tuesday, November 12th.

Citius Pharmaceuticals Stock Performance

CTXR stock traded down $0.05 during trading on Monday, hitting $2.65. 12,269 shares of the company’s stock traded hands, compared to its average volume of 109,991. Citius Pharmaceuticals has a 52 week low of $2.44 and a 52 week high of $26.75. The stock has a market capitalization of $22.72 million, a price-to-earnings ratio of -0.44 and a beta of 1.29. The business has a fifty day simple moving average of $3.33 and a 200 day simple moving average of $9.91.

Citius Pharmaceuticals Company Profile

Citius Pharmaceuticals, Inc, a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome.